Evaluation of prophylactic anticoagulation, deep venous thrombosis, and heparin-induced thrombocytopenia in 21 burn centers in Germany, Austria, and Switzerland

Annals of Plastic Surgery

Volumn 67, Issue 1, 2011, Pages 17-24

  Busche, Marc N ^a   Herold, Christian ^a   Krämer, Robert ^a   Knobloch, Karsten ^a   Vogt, Peter M ^a   Rennekampff, Hans Oliver ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

argatroban; deep venous thrombosis; DVT; heparin induced thrombocytopenia; HIT; LMWH; low molecular weight heparin; prophylactic anticoagulation; UFH; unfractionated heparin; venous thromboembolic event; VTE

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ARTICLE; AUSTRIA; BURN; CHEMICALLY INDUCED DISORDER; GERMANY; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; QUESTIONNAIRE; SWITZERLAND; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ANTICOAGULANTS; AUSTRIA; BURN UNITS; GERMANY; HEPARIN; HUMANS; INCIDENCE; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; SWITZERLAND; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 79959750244     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31821bd4bc     Document Type: Conference Paper

References (36)

1. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med. 1976;295:237-241.
2. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet. 1973;136: 409-416.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1336.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292. (Pubitemid 32372963)
5. Everett BM, Yeh R, Foo SY, et al. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007;83:592-597. (Pubitemid 46135456)
6. Stribling WK, Slaughter TF, Houle TT, et al. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J. 2007;153: 900-906. (Pubitemid 46809845)
7. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518-2524. (Pubitemid 37385796)
8. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955-2959. (Pubitemid 36857979)
9. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
10. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparindependent antibodies. Br J Haematol. 2005;128:837-841. (Pubitemid 40444878)
11. Scott JR, Klein MB, Gernsheimer T, et al. Arterial and venous complications of heparin-induced thrombocytopenia in burn patients. J Burn Care Res. 2007;28:71-75. (Pubitemid 46087859)
12. Busche MN, Peters T, Knobloch K, et al. Heparin-induced thrombocytopenia in a nonthrombocytopenic patient with toxic epidermal necrolysis causing fatal outcome: is HIT still a HIT? J Burn Care Res. 2009;30:747-751.
13. Phelan BK. Heparin-associated thrombosis without thrombocytopenia. Ann Intern Med. 1983;99:637-638. (Pubitemid 14235401)
14. Hach-Wunderle V, Kainer K, Krug B, et al. Heparin-associated thrombosis despite normal platelet counts. Lancet. 1994;344:469-470. (Pubitemid 24248255)
15. Klement D, Rammos S, Kries R, et al. Heparin as a cause of thrombus progression. Eur J Pediatr. 1996;155:11-14.
16. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99:2530-2536. (Pubitemid 29228283)
17. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106: 629-635. (Pubitemid 29279299)
18. Kappers-Klunne MC, Boon DM, Hop WC, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol. 1997;96:442-446. (Pubitemid 27087224)
19. Greinacher A, Eichler P, Lietz T, et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106: 2921-2922. (Pubitemid 41510775)
20. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:311S-3337S.
21. Takashima Y. Blood platelets in severely injured burned patients. Burns. 1997;23:591-595. (Pubitemid 28142383)
22. Wang Y, Tang HT, Xia ZF, et al. Factors affecting survival in adult patients with massive burns. Burns. 2010;36:57-64.
23. Lindhoff-Last E, Gerdsen F, Ackermann H, et al. Determination of heparinplatelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886-890. (Pubitemid 32634754)
24. Suh JS, Malik MI, Aster RH, et al. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997;54:196-201. (Pubitemid 27148257)
25. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2:2133-2137. (Pubitemid 40185772)
26. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507. (Pubitemid 126335970)
27. Beiderlinden M, Treschan TA, Gorlinger K, et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007;41:749-754. (Pubitemid 46752654)
28. Kiser TH, Jung R, MacLaren R, et al. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005;25:1736-1745. (Pubitemid 41790097)
29. Koster A, Hentschel T, Groman T, et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg. 2007;133:1376-1377. (Pubitemid 46656385)
30. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103: 1838-1843. (Pubitemid 32328395)
31. Lubenow N, Lietz T, Farner B, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood. 2004;104:3072-3077. (Pubitemid 39507121)
32. Jokuszies A, Niederbichler A, Herold C, et al. The current evidence-based guidelines regarding prophylaxis of venous thrombembolism and their relevance for plastic surgery in German . Handchir Mikrochir Plast Chir. 2010;42:251-259.
33. Pannucci CJ, Osborne NH, Wahl WL. Venous thromboembolism in thermally injured patients: analysis of the National Burn Repository. J Burn Care Res. 2011;32:6-12.
34. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S-453S. (Pubitemid 351894916)
35. Lin H, Faraklas I, Cochran A, et al. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res. 2011;32:1-5.
36. Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies-distinguishing "signal" from "noise." Thromb Haemost. 2008;100:523-524.